此页面是自动翻译的，不保证翻译的准确性。请参阅 英文版 对于源文本。

Proteomic Study of Urinary Stone Disease

2009年9月2日 更新者：Lawson Health Research Institute

Urinary Proteomic Profiling Using ProteinChip SELDI-TOF-MS: A Potential Means of Identifying Protein Biomarkers of Urinary Stone Formers

Urinary protein levels are not routinely measured in stone patients while there is strong evidence that proteins play a role in the etiology of stones. The purpose of this study is to examine the urinary and serum proteins of stone formers compared to healthy subjects utilizing the high throughput method, Surface Enhanced Laser Desorption/Ionization (SELDI). We hypothesize that there is a unique set of proteins expressed in serum and urine in stone patients that can be detected by SELDI. Ultimately, this will better our understanding of stone disease and help develop new prevention strategies.

研究概览

地位

完全的

条件

详细说明

Urinary stone disease affects 10% of the Canadian population during their lifetime and approximately half of these patients will have another episode within ten years. Currently, patients undergo metabolic testing (serum and 24 hour urine tests) to identify modifiable risk factors; however, no modifiable risk factors are identified in many patients, yet they continue to form stones. New techniques must be developed to identify stone patients at risk for future recurrences and ultimately to develop more specific prevention strategies.

Urinary protein levels are not routinely measured in stone patients while there is strong evidence that proteins play a role in the etiology of stones. The purpose of this study is to examine the urinary and serum proteins of stone formers compared to healthy subjects utilizing the high throughput method, Surface Enhanced Laser Desorption/Ionization (SELDI). We hypothesize that there is a unique set of proteins expressed in serum and urine in stone patients that can be detected by SELDI. Once a protein is identified as a biomarker, a specific assay similar to a quick and affordable dipstick test may be developed to identify those stone patients at risk of future stones. Ultimately, this will better our understanding of stone disease and help develop new prevention strategies.

Comparisons: protein profiles (serum/urine) of stone patients both during the presence of a stone and 6 weeks after they have passed it. comparison of stone profiles of stone patients with controls (non-forming stone patients).

研究类型

观察性的

注册 (实际的)

20

联系人和位置

本节提供了进行研究的人员的详细联系信息，以及有关进行该研究的地点的信息。

学习地点

  • 加拿大
    • Ontario
      • London、Ontario、加拿大、N6A 4V2
        • St. Joseph's Health Care London

参与标准

研究人员寻找符合特定描述的人，称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 65年 (成人、年长者)

接受健康志愿者

是的

有资格学习的性别

全部

取样方法

非概率样本

研究人群

This observational study will compare stone formers meeting the inclusion criteria with a cohort of age and sex matched non-stone formers as controls.

描述

Inclusion Criteria:

  • Controls:

    • Ages 18 to 65 years of age
    • No history of stone disease and no radiographical evidence of stone (as demonstrated by negative ultrasound)
    • No family history of stones
    • Healthy and no autoimmune or systemic disease that may affect renal function (see exclusion criteria)

Stone patients

  • Ages 18 to 65 years of age
  • Solitary stone of any size, in any location along the urinary tract (except lower renal calyceal stones and bladder stones)
  • Radiology of any modality proving the existence of the stone (ultrasound, computed tomography, intravenous pyelogram, kidney-ureter-bladder x-ray)

Exclusion Criteria:

  • ALL:

    • Pregnant females
    • Male patients treated for with benign prostate hyperplasia (BPH) (ongoing medical treatment or surgical intervention within 6 months)
    • Positive urine culture
    • Any cancer (excluding superficial skin, brain)
    • Chronic Recurrent urinary infections (prostate, cystitis, vaginosis/vaginitis)
    • Gross hematuria
    • Autoimmune disease that may affect renal function (eg Systemic lupus erythematosus)
    • Renal dysfunction or its common causes:
    • Diabetes
    • Uncontrolled hypertension (with concurrent microalbuminuria) (diastolic BP > 90 mmHg)
    • glomerulonephritis
    • Renal transplant
    • Genetic stone disease (e.g. Cystine stones, xanthinuria)
    • Medullary sponge kidney, or other renal anomalies such as horseshoe kidney
    • GI disorders: Inflammatory bowel disease, short bowel
    • Hypercalcemic disorders (hyperparathyroidism, sarcoidosis, Paget's disease)
    • Renal tubular acidosis
    • Immunodeficient patients e.g. HIV (indinavir stones)
    • Unable to provide informed consent
    • Anyone in the opinion of the investigator who would be inappropriate

Controls :

  • In addition to criteria above.....
  • persistent thiazide use
  • Family history of stones (this will exclude any genetic factors since a positive family history increases the risk of urolithiasis)

学习计划

本节提供研究计划的详细信息，包括研究的设计方式和研究的衡量标准。

研究是如何设计的？

设计细节

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

Lawson Health Research Institute

合作者

University of Western Ontario, Canada
The Physicians' Services Incorporated Foundation

调查人员

  • 首席研究员：John D Denstedt, MD, FRCSC、The University of Western Ontario (Professor)

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查，以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2005年1月1日

初级完成 (实际的)

2008年11月1日

研究完成 (实际的)

2008年11月1日

研究注册日期

首次提交

2005年9月12日

首先提交符合 QC 标准的

2005年9月12日

首次发布 (估计)

2005年9月20日

研究记录更新

最后更新发布 (估计)

2009年9月3日

上次提交的符合 QC 标准的更新

2009年9月2日

最后验证

2009年9月1日

更多信息

与本研究相关的术语

关键字

其他相关的 MeSH 术语

其他研究编号

  • R-04-481
  • PSI 04-041

此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.

订阅